Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd. Cumulus Neuroscience enters the Japanese market through a partnership with Shionogi, aiming to enhance cognitive biomarker research for innovative therapies.

Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd. #Japan #Osaka #Cumulus_Neuroscience #Shionogi #NeuLogiq_Platform

Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair Cumulus Neuroscience has appointed Dr. Ricardo Sáinz Fuertes as the new Chair of the Board, succeeding Dr. Ruth McKernan. His expertise aims to lead the company into the next phase of growth.

Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair #United_Kingdom #digital_health #Belfast #Cumulus_Neuroscience #NeuLogiq_Platform

Cumulus Neuroscience Confirms Neuroplasticity Measurement Using Innovative EEG Technology Cumulus Neuroscience has published a new study validating a low-burden method for assessing neuroplasticity, revolutionizing clinical trials.

Cumulus Neuroscience Confirms Neuroplasticity Measurement Using Innovative EEG Technology #United_Kingdom #EEG_Technology #Belfast #Cumulus_Neuroscience #Neuroplasticity

Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025 Cumulus Neuroscience unveiled pivotal findings at CTAD 2025, showcasing how at-home digital endpoints enhance trial efficiency and cost-effectiveness in Alzheimer's research.

Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025 #United_States #San_Diego #Alzheimer's_Disease #Cumulus_Neuroscience #NeuLogiq

Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences Cumulus Neuroscience has presented groundbreaking findings at prominent neuroscience events, highlighting advancements in clinical trials and digital health technology.

Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences #United_Kingdom #Clinical_Trials #Amsterdam #Cumulus_Neuroscience #NeuLogiq

Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors Cumulus Neuroscience, a leader in digital health, announces Robert Ballantine's appointment to its board, enhancing its commitment to neuroscience innovations.

Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors #United_Kingdom #Belfast #Cumulus_Neuroscience #NeuLogiq #Robert_Ballantine

Revolutionizing Alzheimer's Diagnosis with a 3-Minute EEG Test Cumulus Neuroscience has developed a pioneering 3-minute EEG test that can detect memory impairment, offering potential for earlier Alzheimer's diagnosis and improved patient care.

Revolutionizing Alzheimer's Diagnosis with a 3-Minute EEG Test #United_Kingdom #Alzheimer's #Belfast #Cumulus_Neuroscience #Fastball_EEG

Cumulus Neuroscience Showcases Breakthrough Findings on Alzheimer's at AAIC 2025 Annual Meeting At the AAIC 2025 Annual Meeting, Cumulus Neuroscience presented insights from the CNS-101 study, highlighting the effectiveness of at-home cognitive assessments for Alzheimer's patients.

Cumulus Neuroscience Showcases Breakthrough Findings on Alzheimer's at AAIC 2025 Annual Meeting #Canada #Toronto #Alzheimer's #Cumulus_Neuroscience #CNS-101

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials Cumulus Neuroscience presents groundbreaking findings demonstrating the NeuLogiq® Platform's ability to identify key electrophysiological signals in patients with Major Depressive Disorder, enhancing clinical trials.

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials #United_States #Scottsdale,_Arizona #Cumulus_Neuroscience #Major_Depressive_Disorder #NeuLogiq_Platform

Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting Cumulus Neuroscience presented pivotal data at the AD/PD 2025 Annual Meeting, validating its NeuLogiq® Platform for Alzheimer's and ALS-FTD assessments.

Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting #None #Vienna #Alzheimer's_Disease #Cumulus_Neuroscience #NeuLogiq